The estimated Net Worth of Maria Sainz is at least $859 mil dollars as of 23 February 2023. Ms. Sainz owns over 724 units of Orthofix Medical Inc stock worth over $79,901 and over the last 16 years she sold OFIX stock worth over $524,076. In addition, she makes $254,981 as Independent Director at Orthofix Medical Inc.
Maria has made over 3 trades of the Orthofix Medical Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she sold 724 units of OFIX stock worth $139,732 on 23 February 2023.
The largest trade she's ever made was selling 4,157 units of Orthofix Medical Inc stock on 10 June 2016 worth over $192,594. On average, Maria trades about 113 units every 50 days since 2008. As of 23 February 2023 she still owns at least 4,592 units of Orthofix Medical Inc stock.
You can see the complete history of Ms. Sainz stock trades at the bottom of the page.
Maria Sainz is Independent Director of the Company. She became a director of Orthofix in November 2012, after previously having served on the Board from June 2008 to September 2011. Since May 2018, she has served as President & CEO of AEGEA Medical, Inc., a privately-held women’s health company in the field of endometrial ablation. From April 2012 to June 2017, she was the President and Chief Executive Officer, and a director, of CardioKinetix Inc., a heart failure related medical device company. From April 2008 to October 2011, she was President and Chief Executive Officer of Concentric Medical, Inc., a company developing and commercializing devices to perform mechanical clot removal post-stroke, which was sold to Stryker Corporate in October 2011. Upon this acquisition, she served as General Manager of the Stryker Neurovascular business unit until April 2012. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, Ms. Sainz was the Vice President of Global Marketing – Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Master’s Degree in International Management from American Graduate School of International Management. Ms. Sainz has served as a director of Avanos Medical, Inc. (formerly Halyard Health, Inc.) since February 2015, of Iridex Corporation since April 2018, and of Levita Magnetics, a privately-held company, since October 2017. Her service as a director of Iridex will end in June 2020, when her current term expires. Ms. Sainz previously served as a director of The Spectranetics Corporation from 2010 until its sale in August 2017, and of MRI Interventions, Inc. from January 2014 to May 2018.
As the Independent Director of Orthofix Medical Inc, the total compensation of Maria Sainz at Orthofix Medical Inc is $254,981. There are 12 executives at Orthofix Medical Inc getting paid more, with Jon Serbousek having the highest compensation of $4,076,200.
Maria Sainz is 54, she's been the Independent Director of Orthofix Medical Inc since 2012. There are 14 older and 2 younger executives at Orthofix Medical Inc. The oldest executive at Orthofix Medical Inc is Ronald Matricaria, 77, who is the Independent Chairman of the Board.
Maria's mailing address filed with the SEC is C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA, CA, 95054.
Over the last 22 years, insiders at Orthofix Medical Inc have traded over $19,062,472 worth of Orthofix Medical Inc stock and bought 182,076 units worth $5,806,101 . The most active insiders traders include Stuart Essig, Charles R. Kummeth y Alexis V Lukianov. On average, Orthofix Medical Inc executives and independent directors trade stock every 53 days with the average trade being worth of $179,237. The most recent stock trade was executed by Kevin J. Kenny on 8 January 2024, trading 5,959 units of OFIX stock currently worth $103,687.
orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing
Orthofix Medical Inc executives and other stock owners filed with the SEC include: